

—

”

”

-

-

”

”

03.01.50 —

:

. -

, .

:

. -

, . .

. -

, .

, 2012

154
17 31 . 203
, 32 171 .
” ”,

12:00 ” ” - , . ” .
” 1

www.mu-pleven.bg

	3
	4
	6
	7
	8
	11
1.	11
2.	18
3.		22
4.	27
	<i>Chlamydia pneumoniae</i> <i>Mycoplasma pneumonia</i>	
5.	,	31
6.	34
	41
1.	41
2.	45
3.		48
4.	49
	, <i>Chlamydia pneumonia</i> <i>Mycoplasma neumona</i> .	
5.	,	52
6.	54
	58
	59
	60
	-	60
	61
	62

	-			
	-			
	-			
	-			
	-			
	-			
	-			
	-			
	-			
	-	-		-
	-			
	-			
	-			
	-			
	-			
	-		-	
	-			
	-	-		
	-			
IgA	-			
IgM	-			M
IgG	-			G
Ig	-			
Ag	-a			
- Ly	-T			
- Ly	-			
Leu	-			
Lym	-			
	-			
Gr	-			
ELISA	-Enzyme-linked immunosorbent assay			
WHO	-			
CRP	- C-			
TLR	-	-		
IL-1	-		1	

IL-4	-	4
IL-5	-	5
IL-6	-	6
IL-9	-	9
IL-13	-	13
TNF	-	-
NK	-	
h	-	
Tc	-T	
Ab	-	
HIV	-Humman Immunodeficiency Virus	
HLA-DR	-Human Leukocyte Antigens DR molecule	
pO₂	-	
pCO₂	-	
hMPV	-	
PMN	-polymorphonuclear cell	
RI	-Magnetic resonance imaging	

Streptococcus pneumonia

Mycoplasma pneumonia.

Chlamydia pneumonia

- : - .
1. : , .
2. .
3. -
, *Chlamydia pneumoniae* *Mycoplasma pneumoniae*.
,
4. , .
5. .
6. .
7. .



:

964

. 60

:

:

“

“

-

:

-

“

,

“

-

“

,

“

-

“

“

:

60

(03.2010-

03.2011).

:

:

10

,

,

.

:

6

18

;

•

•

-

,

,

;

•

;

•

;

•

.

•

6

:

(

,

,

,

);

•

:

-

,

,

,

,

,

;

•

;

•

,

;

•

-

;

•

;

•

.

.

:

1. _____ ().

2. _____ Hb ;

„AL818”ÄVL;

• - ;
• - ;
• -

„Medica”USA

• -

3. _____

4. _____ ;

5. _____ :

•

(IgA, IgG, IgM)

•

(CD₃+), T (CD₈+), T_h(CD₄+), -Ly(CD₁₉+), NK- (CD₅₆+)- T-Ly

•

, *Chlamydia pneumoniae* IgG, *Chlamydia pneumoniae* IgA, *Mycoplasma pneumoniae* IgG

ELISA.

•

nt u - 5 PPD Quanti

FERON-TB Gold(Cellestis) -

6. _____ -

IBM SPSS Statistics 19.0.

p < 0,05.

•

•


•

•




(03.2010 - 03.2011)

- 964 , 60 (6,2%)
 (.1). 33(55%)
 27(45%) (.2).



■ с пневмония ■ с протрахирана пневмония


:1



■ момчета ■ момичета

2:

10 17 , 1-5 , 5 (. 3). , 4,66±4,28 ,
 - 6 (58%) 1-5 , - 5
 (32%) - (10%) 6 - 1 .




Фигура 3: Разпределение на пациентите по възрастови групи

(12,9%), (12,1%), (5,0%), (1,5%), (13,4%), (25%), (15%), (15%), (4,9%), (1,7%), (4,5%), (1,7%).


1

	n=964		n=60	
III.2010	85	8,8%	9	15%
IV.2010	58	6 %	6	10%
V.2010	71	7,3%	2	3,3%
VI.2010	87	9%	1	1,7%
VII.2010	64	6,6%	9	15%
VIII.2010	43	4,5%	2	3,3%
IX.2010	48	4,9%	9	15%
X.2010	67	7%	3	5%
XI.2010	71	7,4%	15	25%
XII.2010	124	12,9%	3	5%
I.2011	117	12,1%	1	1,7%
II.2011	129	13,4%	0	0%

5).



Фиг.4 : Разпределение по месеци на хоспитализираните деца с пневмония



Фиг 5 : Разпределение по месеци на хоспитализираните деца с протрахирана пневмония

39(65%)
(96,7%)

6(10%)

38-39° – 30(50%)
 \bar{X} - 13,63

18(30%)

22(26%)

42(70%),
(81,7%).

28(46,7%) ,


38(63%),

$\bar{x} - 16,23$. 12
 , 10 - .
 10(16,7%) ,
 12(20%), 12(20%), 11(18,3%),
 5(8,3%)(.2). , 7(11,6%) ,
 $\bar{x} - 12,7$.


2

	(n=60)	
	n	%
	42	70,0
	39	65,0
	6	10,0
	28	46,7
	30	50,0
	38	63,3
	22	36,7
	12	55,0
	10	45,0
	11	18,3
	12	20,0
	10	16,7
	12	20,0
	5	8,3

35(58%) 2(3,3%) 44(73,3%),
 49(81,7%) ,
 48(80%)
 12(20%).
 49(81,7%) -
 10(16,7%) , / - 44(73,3%) ,
 24(40,0%), 14(23,3%)
 (7).



I- ; II- ; III- ; IV- ; V-




I- ; II- ; III- ; IV- ; V- ; VI- ; VII- ; VIII- ; IX- ; X- ; XI-

.3.

3

	(n=60)	
	\bar{X}	SD
	21,75	10,91
Leuc	10,96	6,16
Gr	56,30	18,44
Ly	36,13	16,61
Mo	4,99	3,64



... (

(5)

Quanti FERON-TB Gold

(5),

“ ”

LISA

18(30%)

Chlamydia pneumoniae Ig

9(15%)

Chlamydia pneumoniae IgG

8(13%),

3(5%)

Chlamydia pneumoniae Ig IgG

Mycoplasma pneumoniae IgG

9(15%)

6(10%)

42(70%)

c

(.4).

4

	(n=42)		(n=18)		p
	\bar{X}	SD	\bar{X}	SD	
Chl.pn IgG	0,49	0,17	1,10	0,86	0,002
Chl.pn.IgA	0,51	0,17	1,08	0,78	0,002
Myc.pn.IgG	0,53	0,20	1,24	0,75	<0,001

IgM,

5-7

IgA

IgM,

IgG

2-3

ELISA

2

-

IgA

IgG

” “
 , - *Streptococcus pneumoniae* . “a
 “ , *Chlamydiaceae spp. Mycoplasma*
spp, Legionella pneumophila.

, *Chlamydia pneumoniae* *Mycoplasma pneumoniae* .
 , *Chlamydia psitacii*
 . *Chlamydia trachomatis* ,

3-4

6

18(30%)

(.9).

Chlamydia pneumoniae


15

, *Mycoplasma pneumoniae* -


3, 6
12(66,7%)

6(33,3%) -

(.10).




9:



10:

1-5 (44,4%),
22,2%
4,8±4,90 .


6 - 1 (.11). - 33,3%, - -



6 -1 1 - 5 5
11:

(15%), . . . (25%), (15%)
 (33%) (27%)).


97(94,4%)
 (.12). 14(77,8%)
 , 2(11,1%) -
 (94,4%), $\bar{x} - 18,33$ -
 - 12(66,7%) , 5(27,8%).
 $\bar{x} - 18,06$, 14(77,8%)
 50% 3(16,7%)



12:

I- ; II- ; III- ; IV- ; V- ; VI- ; VII-
 ; VIII- ; IX-

- 8(44,4%), - 5(27,8%) - 9(50,0%),
 1 (.13).



Фигура 13: Извън белодробни симптоми при деца с атипична пневмония

I- ; II- ; III- ; IV-

1 9(50,0%) , 12(66,7%),

– 13(72,2%) .

– 13(72,2%),

8(44,4%) , 4(22,1%) 11(61,1%),

–

8(44,4%), 9(50,0%),

5(27,8%) .

13(72,2%) . 4(22,2%) .

–

15(83,3%), 6(33,3%)

(.5).

–


(66,7%),

(38,9%). 6(33,3%)

(.14).

	(n=18)	
	\bar{X}	SD
	27,28	9,74
Leuc	10,11	3,48
Gr	53,67	20,89
Ly	38,67	18,98
Mo	5,71	5,03
pO₂	66,10	7,34
pCO₂	35,10	5,23

(66,7%),
 (38,9%). 6(33,3%)
 (.14).




14:

1-5	-	27(64,3%)	,	8(44,4%)	.
					5
	-	13(31,0%)	,	6(33,3%)	-
	6	- 1 2(4,8%)		4(22,2%)	(.15).
					- 4,87±4,90
	,	4,58±4,05	.		

12(66,6%)

6(33,3%)



15: Разпределение по възрастови групи при деца с атипични и типични пневмонии

- 33,3% - 21,1%

- 94,4%

76,2%

14(77,8%),
25(59,5%)

2(11,1%)
4(9,5%)

28(66,4%)

(38,1%)

(66,7%)

38°) 59,5%

- \bar{X} - 18,33

\bar{X} - 11,66

- 24(57%)

14(77,8%)
 3(16,7%)
 -10(23,8%).
 (38,9%) (9,5%)
 $\bar{x} - 18,06$

19(45,2%)
 2(13,3%),
 -
 $\bar{x} - 14,19$
 (> 0,1).

(44,4%),
 (50,0%),
 (4,8%),
 6(33,3%),
 (7,1%),
 4(9,5%)
 6(14,2%).
 (.6).

: 6

	(n=18)		(n=42)		P
	n	%	n	%	
	14	77,8	28	66,7	n.s.
	14	77,8	25	59,5	n.s.
	2	11,1	4	9,5	n.s.
	12	66,7	16	38,1	<0,05
	5	27,8	25	59,5	<0,05
	14	77,8	24	57,1	n.s.
	3	16,7	19	45,2	<0,05
	8	44,4	10	23,3	n.s.
	2	11,1	10	23,8	<0,05
-	1	5,6	9	21,4	<0,01
	7	38,9	4	9,5	<0,05
	6	33,3	6	14,3	n.s.
	8	44,4	2	4,8	0,001
	9	50,0	3	7,1	<0,001
	1	5,6	4	9,5	n.s.

35(54,8%)
 23(54,8%)
 9(50,0%) ;
 12(66,7%)

81% 72,2%

85,7%
-
(78,6%);

72,2%
(44,4%),

(.7).


7

	(n=18)		(n=42)		P
	n	%	n	%	
	13	72,2	35	83,3	n.s.
	5	27,8	7	16,7	n.s.
	9	50,0	35	83,33	n.s.
	12	66,7	23	54,8	n.s.
	1	5,6	1	2,4	n.s.
/	4	22,2	6	14,3	n.s.
	13	72,2	36	85,7	n.s.
	8	44,4	16	38,09	n.s.
/	11	61,1	33	78,57	n.s.
	4	22,2	10	23,80	n.s.

22(52,4%) 8(44,4%) 5(27,8%)
 23(54,8%) 9(50,0%)
 20(23,8%) 20(47,6%) ,
 3(16,7%) ,
 - 22,2% 4,81%
 13(72,2%) , 23(31,0%)
 88,1% ,
 6(14,6%) , . . .
 (66,7%)
 2, 2 36,6% -
 (.8).

	(n=42)		(n=18)		p
	\bar{X}	SD	\bar{X}	SD	
	19,3	10,62	27,28	9,74	0,002
Leuc	11,30	6,96	10,11	3,48	n.s.
Gr	57,42	17,45	53,67	20,89	n.s.
Ly	35,04	15,60	38,67	18,98	n.s.
Mo	4,69	2,88	5,71	5,03	n.s.
pO₂	63,39	9,40	66,10	7,34	n.s.
pCO₂	33,53	5,09	35,10	5,23	n.s.

- 34(81,0%) 2,5
 - 5(27,8%)
 , 7(38,9%),
 6(33,3%) (.16).



16:


I-

III-

; II-

Chlamydia pneumoniae *Mycoplasma pneumoniae*

15(83,3%) , *Chlamydia pneumoniae*
 , 6
 - *Mycoplasma pneumoniae* . *Mycoplasma pneumoniae*
 3(16,7%)
 , *Chlamydia pneumoniae* - 5
 1-5 (40,0%),
 (33,3%). *Mycoplasma pneumoniae* , , -
 5 (66,7%), 1-5 (33,3%).
pneu onia 6 -1 4 (26,7%) (.17).
Chlamydia pneumoniae , *Chlamydia pneumoniae*



17:

Chlamydia pneumoniae *Mycoplasma pneumoniae*

Chlamydia pneumoniae ,
Mycoplasma pneumoniae , a *Chlamydia pneumoniae* 73,3%.
 - 73,3% *Chlamydia pneumoniae*
 77,8% *Mycoplasma pneumoniae* .

Chlamydia pneumoniae 11(73,3%)
Mycoplasma pneumoniae 6(66,7%)
Chlamydia pneumoniae 7(77,8%)
Mycoplasma pneumoniae 12(80,0%)
Chlamydia pneumoniae 2(13,3%)
Mycoplasma pneumoniae 1(11,1%)
 46,7%
 22,2%

Chlamydia pneumoniae *Mycoplasma pneumoniae*

	n	%	n	%
	11	73,3	6	66,7
	3	20,0	3	33,3
	12	80,0	7	77,8
	2	13,3	1	11,1
	8	53,3	7	77,8
	11	73,3	9	100
	11	73,3	7	77,8
	2	13,3	0	0,0
	1	6,66	1	11,1
-	1	6,66	0	00,0
	7	46,7	2	22,2
	5	33,3	3	33,3
	7	46,7	2	22,2
	6	40,0	3	33,3
	1	6,66	0	00,0

Chlamydia pneumoniae (46,7%),
Mycoplasma pneumoniae (33,3%),
Chlamydia pneumoniae (33,3%),
Chlamydia pneumoniae (40,0%),
Mycoplasma pneumoniae (22,2%).
Chlamydia pneumoniae 10%
Mycoplasma pneumoniae 33,3%

Chlamydia pneumoniae *Mycoplasma pneumoniae*

(66,7%)
 8(53,3%)
 55,6%.
 3(33,3)
 (.10).
 - 12(80,0%) 4(44,4%)
 (80,0%)
Mycoplasma pneumoniae(55,6%).
Mycoplasma pneumoniae 4(44,4%)
 - 4(44,4%)
Chlamydia pneumoniae 9(60,0%),
 - 7(46,7%), 4(26,7%)

Chlamydia pneumoniae *Mycoplasma pneumoniae*
 10

	n	%	n	%
	12	80,0	4	44,4
	3	20,0	5	55,6
	8	53,3	3	33,3
	10	66,7	5	55,6
	0	00,0	1	11,1
/	12	80,0	5	55,6
	2	13,3	4	44,4
	7	46,7	4	44,4
/	9	60,0	4	44,4
	4	26,7	1	11,1

Leuc 8(53,3%) *Chlamydia pneumoniae*
 4(44,4%) *Mycoplasma pneumoniae*
 - 20.10⁹/l,
 - *Mycoplasma pneumoniae* (55,6%)
Chlamydia pneumoniae (33,3%).
 - 26,7% *Chlamydia pneumoniae* 22,2%

Mycoplasma pneumoniae .

5(33,3%)

Mycoplasma pneumoniae

Chlamydia pneumoniae - 4

2

pneumoniae .

Mycoplasma

11,1%

Mycoplasma pneumoniae .

Chlamydia pneumoniae -26,7%


5(55,6%)

Mycoplasma pneumoniae 4(26,7%)

Chlamydia pneumoniae ,

11(73,3%)

Chlamydia pneumoniae (.18).



■ *Chlamydia pneumoniae* ■ *Mycoplasma pneumoniae*

18:

pneumoniae

88,9%

- 86,7%

Mycoplasma pneumoniae .


Chlamydia

Chlamydia pneumoniae

6(40,0%)

3(20,0%)


(.19).



19:

I- ; II- ; III-

pneumonia 7(46,7%) : 5(55,5%) *Mycoplasma pneumoniae* 28,3%
 3(5,0%) 2(3,3%) : 3(5,0%) *Chl mydia pneumoniae* -
 14(13,3%) , 10(55,6%) , 4 (9,5%)
 5(55,6%) , - 9(60,0%) *Chlamydia pneumoniae*
Mycoplasma pneumoniae (.20).



20:

46(76,7%)

Chlamydia pneumoniae 77,8%
30(50,0%)
(72,2%)


Mycoplasma pneumoniae : 86,7%

44,5%

(.21).


- 77,8% *Mycoplasma*

pneumoniae 66,7% *Chlamydia pneumoniae* .



21:

8(13,3%)
 -
 18(30,0%)
 6(33,3%)
 12(28,6%)
 22(36,7%)
 (73,3%)
 (26,2%)
 (.22).



- естествено хранени
- изкуствено хранени
- до 4 месеца
- повече от 4 месеца

22:

(16,7%) (.11).
 (11,6%)
 21(35,0%)
 (22,2%),
 (10,0%).

11

	(n=18)		(n=42)		P
	n	%	n	%	
	9	50,0	13	31,0	n.s.
	6	33,3	2	4,8	0,007
	8	44,4	9	21,4	n.s.
	10	55,6	4	9,5	<0.001
	9	50,0	12	28,6	n.s.
	5	27,8	7	16,7	n.s.

T-Ly.

(.12).

Hannet I., F. Yuksel, V. Deneys

101

B-Ly

o

12

	(n=60)	
	\bar{X}	SD
IgA	1132,23	283,36
IgG	116,17	43,94
IgM	80,05	23,82
Ly	54,01	14,47
B-ly	24,12	13,57
T-	25,66	10,68
	27,19	9,52
h/Tc	1,07	0,57
NK-	15,62	9,85



T-Ly

43(71,7%)


- (88.3%)

(.23).

pneumonia 7(47,8%) 28(66,7%) *Mycoplasma pneumoniae*, 12(80,0%) *Chlamydia* Th, Tc,
 Th/Tc.
 Th- 75,0%
 A 83,3% (.24). 71,4%



Th, .
 Th
 Ly,
 (.13).
 e
 26(43,3%)
 14(23,3%) -
 - (52,4%) (22,2%) (.25).



:25

Ly

13

	(n=42)		(n=18)		p
	\bar{X}	SD	\bar{X}	SD	
Ly	53,85	14,25	54,39	15,38	n.s.
T-	27,13	10,37	22,22	10,91	n.s.
	26,95	10,68	27,79	5,99	n.s.
h/Tc	1,12	0,56	0,94	0,60	n.s.
NK-	14,40	9,68	18,48	9,93	0,058

2(22,2%)
 4(26,6%)
Chlamydia pneumoniae .


3(20,0%)
 3(33,3%)
Mycoplasma pneumoniae .

h/ .


(47,6%)
Chlamydia pneumoniae

h/Tc
 13(86,7%)
Mycoplasma pneumoniae

Th/T (.26 .27)




h/Tc
 : 26 Th/Tc



27:
 I- Th; II- Tc; III- h/Tc; IV- -Ly


NK-
 - 26(43,3%) , - 14(23,3%) NK-
 -10(55,6%) 16(38,1%)
 (.28).



: 28

NK

B-Ly IgM, IgG, IgA (.29)
 (.14).




29:

19(31,7%)
22,2%,
B-Ly
,
28,3% B-Ly
,
.30,9% (.30).

14

	(n=42)		(n=18)		p
	\bar{X}	SD	\bar{X}	SD	
IgA	1112,81	272,48	1177,56	310,64	n.s.
IgG	121,10	45,78	104,67	38,02	n.s.
IgM	77,62	24,36	85,72	22,12	n.s.
B-ly	25,38	13,46	21,17	13,75	n.s.



: 30

46(76,7%)
- 18(30,0%)

6(33,3%)

IgG 39(65,0%)

IgG

(61,1%)

(66,7%).

33(55,0%)

IgM, a

37(61,7%) -

IgA(.31).

IgM IgA

IgM

IgA


10(55,6%)

IgA


27(64,3%)

IgM

23(66,7%)



31 :



:

(03.2010-03.2011)

964

6,2%

Vaughan (2002)

1-5

*(Kumar),
.Yokin*

(Lodha)

5

2

1-5

*British Thoracic Society
. Kilic (2004)*

(2011)

(55%).

Clark (2007)

, Couriel (2002)

Senstad, a Ostapchuk(2004)

(-).

(81,7%),

(70%),

-

(58,3%).

(\bar{X} - 16,23 - (63,3%).

(73,3%)

(, , ,). *Lodha*

(20,0%), (16,7%).

8,3%

(


).

(73,3%) (58,3%).

(80,0%)

CRP.

50,0%



(/)

(1,97). 3,3%

Lodha (2003), Kumar (2009).

Couirel (2002)

12,0%

38

Vanghan

(2002)

British Thoracic Society

7-

10

6%

(*Mycoplasma pneumoniae* , *Chlamydia pneumoniae*).

60-

Arancibia 20,0%

. Kumar (2009)

19,2% , Vanghan (2009)

ycobacterium tuberculosis

8,3%

Mantox

QuantiFERON-TB Gold

ELISA,

Chlamydia pneumoniae IgA IgG

30,0%

Mycoplasma pneumoniae IgG

Joun J (2010) iyashita (2002).

25,0%

Chlamydia pneumoniae
pneumonia

15,0%

Mycoplasma

10,0%

Julish (2002), Stelmach (2005),

(2005).

Chlamydia pneumoniae

Mycoplasma pneumoniae ,

(66,7%).

Baer (2003), Somer (2006), Korppi (2004)

5-15

Principi (2001), Kicinski (2011), Waites (2004)

Chlamydia

pneumoniae Mycoplasma pneumoniae

5 . *Block*

3

-12

1-5 (44,4%).

(2001).

- *Stawarski (2001) Principi*

icinski (2011).

Iwanczak (2001)

\bar{X} - 18,06

Norman

Kicinski (2011)

77,8%

-11,1%.

1-8,5%.

14%,

Chlamydia pneumoniae

Mycoplasma pneumoniae

Mycoplasma pneumoniae Waites.
 () - () -
 (2003) 22,7%
 5,6%
 Waites (2004),
Mycoplasma pneumoniae , - (25,0%), -
 , .
 , , .
 , - .
 -
 Puljiz (2005) 44,4%,
 Waites (2004).
 (2003) ,
 , Agarwal (2009) 16,6%
Mycoplasma pneumoniae Youn (2010) *Mycoplasma*
 50,0% .
 . Youn
Mycoplasma pneumoniae .
 -
 Esposito (2001), Kicinski (2011), Agarwal (2009). British
 Thoracic Society (2011), .
 , ,
 ,

(Korppi, Dennehy (2010)),

33,3%

–Wubbel (1999), Juven

(2000), Rudan (2008), Katasova (2009), Dennehy (2010), Harris (2011).

1-5

Esposito (2001)

Suarez (2011), Agarwal (2009) , PMN
 ,
 Puljiz , Jadavji (1997). Esposito (2002) , CRP Leuc
 - Streptococcus pneumonia
 ,
 ,
 .
 -
 , -
 ,
 .
 -75% Agauarwal
 (2003), 85,8% Kicinski (2011). John (2001) Jadavji (1997)

Chlamydia pneumoniae* *Mycoplasma pneumoniae

Chlamydia pneumoniae *Mycoplasma pneumoniae*
Chlamydia pneumoniae *Mycoplasma pneumoniae*
pneumoniae ,
Mycoplasma pneumoniae - (Puljiz, Kicinski, Agarwal) Ouchi
 (1999) , *Chlamydia pneumoniae*
 ,
 - *Chlamydia pneumoniae* - 25,0%
 , *Mycoplasma pneumoniae* - 15%,
 10% .

. Andersen (1999) , *Chlamydia pneumoniae*
 ,
 (2005) -
Streptococcus pneumoniae ,

ikka (2000) 10%, Heiskanen-Kosma (1999) – 23,0%,
60,0%.

pneumonia *Chlamydia pneumoniae* *Mycoplasma pneumoniae*
pneumonia - 1-5, *Chlamydia pneumoniae*
pneumonia - *Mycoplasma pneumoniae*
1 *Mycoplasma pneumoniae*,
Korppi (2004) Waites (119,191). Cimolai (1998)
(1983), *Mycoplasma pneumoniae*

Principi (2001) *Chlamydia pneumoniae*
Mycoplasma pneumoniae (14,5%) 8-14
5

Chlamydia pneumoniae *Mycoplasma pneumoniae*,
Youn (2010),
Mycoplasma pneumoniae

Mycoplasma pneumoniae -
- a
Mycoplasma pneumoniae
Mycoplasma pneumoniae . Kicinski (2010)
Chlamydia pneumoniae .
Mycoplasma pneumoniae
- , *Chlamydia pneumoniae*
Chlamydia pneumoniae . Puljuz

Chlamydia pneumoniae *Mycoplasma pneumoniae* .

John (2001)

2 .

Chlamydia pneumoniae

Chlamydia pneumoniae -

Cimolai (1998),

Mycoplasma pneumoniae ,

Chlamydia pneumoniae *Mycoplasma pneumoniae* .

Youn

Mycoplasma pneumoniae .

Mycoplasma pneumoniae ,

Mycoplasma pneumoniae

Mycoplasma pneumoniae

John (2001)

Kicinski (2011)

Suarez (2001)

Cimolai (1998)

Mycoplasma

pneumoniae

Mycoplasma

pneumoniae

) -

Mycoplasma pneumoniae

(

Waites (2004).

Chlamydia pneumoniae

-

Mycoplasma pneumoniae

Waites

8,3%

10-14, 21

28,3%

(23,3%).

35,5%

10,0% -

Ciprandi (2006)

Chlamydia

pneumoniae

Schmidt (2003)

Chlamydia pneumoniae,

IgE
Ferrari (2002)

IgG

Chlamydia pneumoniae a
Chlamydia pneumoniae
Ferrari (2002).

(2004) , , Kraft (2002) , . Briscione

5,0%

Chlamydia pneumoniae ,

Chlamydia pneumoniae .

Webley (2005) ,

10,0%

5,75
Ramarkrishnan (2006)

. Bhaskaran (2003)

Mycoplasma pneumoniae . Shulman

(76,6%), 50,0%

de Martino (2007),

Jartsev (2005)

()

36,7%

20,0%

4 33,3%

4

(1998)
(60,0%)

11,6%

Vaunghan,

-Ly

(20,0%)

(20,0%)

IgA

IgA(13,3%). *Ozkan (2005)*

Ig

-Ly

T-Ly

16,7%

(. .)

20,0%

T-Ly(71,7%),

Th Th/Tc

5

h (2005) T-Ly Th/Tc 1,5

Yulish (2002) Tc(Th

), - .

-

IgG(39,0%), -Ly (30,0%), 31,7% -

Yulish(2010) -Ly .

IgA, IgM, IgG, 18,3% .

(23,8%).

(2005), Hahn, Halme (2000) ,

-

(- T-Ly, h,Th/Tc).

(Th/Tc).

. *Halme* (2000) Dobbs Tc

h .

Tc. , - h

,

Yulish (2002).

Chan (1995) *Mycoplasma pneumoniae* , *Stelmach* (2005)

Th, 1 .

Mycoplasma pneumoniae .

Mycoplasma pneumoniae

Th(88,9%), T Ly (88,9%)

- c(22,2%).

,

.

,

,

,

, *Zueva* , ,

- ,

(2010)

Chlamydia pneumoniae *Mycoplasma pneumoniae*

, NK , -Ly.

1 , 12%

1.

1-5

2.

3.

(

4.

5.

6.

7.

:

1. 30,0%

Chlamydiae pneumoniae *Mycoplasmae pneumoniae*.

2.

3.

4.

5.

6.

7.

8.

9.

T-Ly, Th,

(88,4%).

1.

Chlamydia pneumoniae

Mycoplasma pneumoniae.

2.

-

3.

4.

1.

2.

3.

pneumoniae (30,0%)

Chlamydia pneumoniae *Mycoplasma*

4.

, -

5.

;

АЛГОРИТЪМ НА ПОВЕДЕНИЕ ПРИ ПРОТРАХИРАНИ ПНЕВМОНИИ

